GLPwatch
Papers (12034)
Page 160 of 201, ranked by citation count.
- The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.
- Correction to "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight".
- Semaglutide-Induced Liver Injury.
- Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome.
- More Unnecessary Imaginary Worlds - Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes.
- CORRECTION: Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?
- Navigating compounded semaglutide: what health care providers need to know.
- Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis.
- Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.
- Tirzepatide for Heart Failure and Obesity.
- Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial.
- Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes.
- Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates.
- [Treatment of an obese diabetic].
- A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats.
- Burden of obesity in patients undergoing dialysis, and hopes associated with semaglutide treatment for transplant listing: An interview study.
- The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice.
- Letter to the editor: Semaglutide-associated recurrent distal intestinal obstruction in cystic fibrosis.
- The Effect of Body Mass Index on the Efficacy of Semaglutide Use at the Time of Total Knee Arthroplasty.
- Tirzepatide alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-κB signaling pathway.
- Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission.
- Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.
- Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.
- Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report.
- Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.
- Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.
- The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?
- Semaglutide Initiation in a Type 2 Diabetes Mellitus, Post-Liver Transplant Patient.
- Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet.
- Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.
- Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases.
- New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
- Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism.
- Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany.
- Comments to the Editor Concerning the Paper Entitled "Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4" Mohamed Abd Elaziz Wassef et al.
- Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
- Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice.
- Exploring Adults' Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study.
- Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
- [Dyslipidemia and obesity 2011. Similarities and differences].
- An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update.
- Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity.
- Exploring the nephroprotective effects of combined finerenone and exenatide therapy in diabetic nephropathy.
- Dulaglutide for type 2 diabetes.
- Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.
- In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
- Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.
- Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.
- Research digest: pioneering an oral GLP-1 receptor agonist.
- Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.
- Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.
- Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.
- Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.
- Life-Threatening Ventricular Fibrillation Linked to High-Dose Tirzepatide-Induced Gastrointestinal Side Effects.
- Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study.
- Exogenous oral application of PYY and exendin-4 impacts upon taste-related behavior and taste perception in wild-type mice.
- TREATMENT OF DIABETES MELLITUS IN A GOLDEN LION TAMARIN (LEONTOPITHECUS ROSALIA) WITH THE GLUCAGON-LIKE PEPTIDE-1 MIMETIC EXENATIDE.
- Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
- Liraglutide and DPP-4 inhibitors - side effects comparative clinical study.